EPIX - ESSA Pharma Inc.
IEX Last Trade
1.63
0.020 1.227%
Share volume: 0
Last Updated: Thu 26 Dec 2024 03:30:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
3.82%
PREVIOUS CLOSE
CHG
CHG%
$1.61
0.02
1.24%
Fundamental analysis
27%
Profitability
27%
Dept financing
13%
Liquidity
50%
Performance
25%
Performance
5 Days
0.63%
1 Month
-10.56%
3 Months
-73.56%
6 Months
-66.80%
1 Year
-76.29%
2 Year
-33.47%
Key data
Stock price
$1.63
DAY RANGE
N/A - N/A
52 WEEK RANGE
$1.60 - $11.67
52 WEEK CHANGE
-$76.97
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: David R. Parkinson
Region: US
Website: essapharma.com
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: essapharma.com
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
ESSA Pharma Inc. focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study. The company has collaboration agreements with Caris Life Sciences, Inc. and Bayer Consumer Care AG.
Recent news